SCHEMBL14804375

SCHEMBL14804375

CN(C)C(=O)Nc1cncc(-c2ccc3[nH]nc(C(=O)Nc4cccc(Cc5ccccc5)c4)c3c2)c1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 17/20 0.74
CLK2 P49760 10/20 0.74
CLK3 P49761 9/20 0.74
WNT1 P04628 11/20 0.53
CDK2 P24941 3/20 0.49
CDK7 P50613 2/20 0.49
DYRK3 O43781 1/20 0.49
MAP4K4 O95819 1/20 0.49
CDK1 P06493 1/20 0.49
MARK3 P27448 1/20 0.49
GSK3B P49841 1/20 0.49
CSNK2A1 P68400 1/20 0.49
CSNK1G2 P78368 1/20 0.49
CDK5 Q00535 1/20 0.49
MAP4K2 Q12851 1/20 0.49
PRKAA1 Q13131 1/20 0.49
CAMK2B Q13554 1/20 0.49
CAMK2G Q13555 1/20 0.49
CAMK2D Q13557 1/20 0.49
NTRK3 Q16288 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14792822 0.95 DYRK1A (0.73) DYRK1ACLK2CLK3WNT1CDK2
SCHEMBL14804430 0.91 DYRK1A (0.75) DYRK1ACLK2CLK3WNT1GSK3B
SCHEMBL14792173 0.90 DYRK1A (0.86) DYRK1ACLK2CLK3WNT1CDK2
SCHEMBL14803858 0.88 DYRK1A (0.71) DYRK1ACLK2CLK3WNT1
SCHEMBL14804376 0.87 DYRK1A (0.67) DYRK1ACLK2CLK3WNT1GSK3B
SCHEMBL14804373 0.87 CSNK2A1 (0.59) DYRK1ACLK2CLK3WNT1CSNK2A1
SCHEMBL14804344 0.86 DYRK1A (0.79) DYRK1ACLK2CLK3WNT1GSK3B
SCHEMBL14804367 0.86 DYRK1A (0.55) DYRK1ACLK2CLK3WNT1CDK2
SCHEMBL14792506 0.85 DYRK1A (0.74) DYRK1ACLK2CLK3WNT1GSK3B
SCHEMBL14785591 0.85 DYRK1A (1.00) DYRK1ACLK2CLK3WNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130079329-A1 INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/Beta-CATENIN SIGNALING PATHWAY INHIBITORS VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) 2013-03-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130079329-A1 INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/Beta-CATENIN SIGNALING PATHWAY INHIBITORS WNT3, WNT1, WNT3A DYRK1A 733/4885CLK2 1021/4885CLK3 570/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.